Back

Donor HLA class 1 evolutionary divergence and late allograft rejection after liver transplantation in children: an emulated target trial.

Dumortier, J.; hamada, s.; wischlen, e.; mandier, c.; laverdure, n.; boillot, o.; kounis, i.; Allain, V.; Hervieux, V.; Collardeau-Frachon, s. a.; Dubois, V.; Feray, C.

2024-09-15 transplantation
10.1101/2024.09.13.24313304
Show abstract

HLA evolutionary divergence (HED), a continuous metric quantifying the differences between each amino acid of two homologous HLA alleles, reflects the importance of the immunopeptidome presented to T lymphocytes. It has been associated with rejection after liver transplantation. This retrospective cohort study aimed to analyze the potential effect of donor or recipient HED on liver transplant rejection in a new series of patients transplanted during childhood and followed in adulthood. The study included 120 children who had been transplanted between 1991 and 2010 and were followed by routine biopsies and histological evaluations with a median of 14.1 years post-LT. Liver biopsies were performed routinely 1, 5, 10 and 20 years after transplantation and in the event of liver dysfunction. HED was calculated using the physicochemical Grantham distance for donor and recipient class I (HLA-A, -B, -C) and class II (HLA-DRB1, -DQB1) alleles. The influence of HED on rejection was analyzed using IPW and target trial emulation using the g method. Based on the IPW score, donor HED class I was correlated with the occurrence of late (>90 days) rejection (HR, 1.19, 95% CI: 1.01-1.40) independently of HLA mismatches, donor age and initial induction. This emulated target trial confirmed that donor HED class I has a causal effect on liver graft rejection and this relationship was observed long-term.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
Transplantation
based on 11 papers
Top 0.1%
22.6%
2
American Journal of Transplantation
based on 13 papers
Top 0.1%
19.5%
3
Kidney International
based on 11 papers
Top 0.2%
8.7%
50% of probability mass above
4
Frontiers in Immunology
based on 140 papers
Top 1%
6.1%
5
Scientific Reports
based on 701 papers
Top 35%
5.2%
6
Journal of Clinical Medicine
based on 77 papers
Top 2%
5.2%
7
Frontiers in Medicine
based on 99 papers
Top 6%
2.8%
8
PLOS ONE
based on 1737 papers
Top 80%
2.8%
9
Journal of Clinical Virology
based on 54 papers
Top 1%
2.7%
10
Journal of Clinical Investigation
based on 50 papers
Top 1%
2.1%
11
Vaccines
based on 131 papers
Top 3%
2.1%
12
Science Translational Medicine
based on 40 papers
Top 2%
1.8%
13
Cell Reports Medicine
based on 49 papers
Top 3%
1.5%
14
Journal of the American Society of Nephrology
based on 19 papers
Top 0.9%
1.5%
15
Nature Communications
based on 483 papers
Top 32%
1.5%
16
eLife
based on 262 papers
Top 25%
1.0%
17
Kidney360
based on 14 papers
Top 1%
0.9%
18
eClinicalMedicine
based on 55 papers
Top 4%
0.9%
19
Blood
based on 14 papers
Top 1%
0.8%
20
npj Vaccines
based on 18 papers
Top 0.8%
0.8%
21
iScience
based on 74 papers
Top 7%
0.8%
22
Advanced Science
based on 12 papers
Top 2%
0.8%
23
JAMA Network Open
based on 125 papers
Top 19%
0.8%
24
Statistics in Medicine
based on 17 papers
Top 1%
0.5%
25
Kidney International Reports
based on 11 papers
Top 0.9%
0.5%
26
International Journal of Cardiology
based on 13 papers
Top 4%
0.5%